| Authors: |
Lee SJ; Clinical Research Division and Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington. Electronic address: sjlee@fredhutch.org., Williams KM; Aflac Blood and Cancer Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta Georgia., Sarantopoulos S; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, North Carolina., Kitko CL; Vanderbilt University Medical Center, Nashville, Tennessee., Cutler C; Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, Massachusetts., Pidala J; Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Hill GR; Clinical Research Division and Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington., DeFilipp Z; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, Massachusetts., Greinix HT; Division of Hematology, Medical University, Graz, Austria., Wolff D; Department of Internal Medicine III, University Hospital Regensburg, Germany., Paczesny S; Hollings Cancer Center, Department of Immunology, Medical University of South Carolina, Charleston, South Carolina., Cuvelier GDE; Pediatric Oncology and Transplantation, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada., Schultz KR; BC Children's Hospital Research Institute and University of BC, Vancouver, British Columbia, Canada., Pavletic SZ; National Cancer Institute, Center for Cancer Research, Immune Deficiency Cellular Therapy Program, National Institutes of Health, Bethesda, Maryland. Electronic address: pavletics@outlook.com. |
